Телефон
Aspen entered the pharmaceutical market of Russia and the CIS in 2014 after acquiring the oncology and antithrombotic portfolios from GlaxoSmithKline (GSK), as well as the hormonal drugs portfolio (women's and men's health) from Merck Sharp & Dohme with production sites in Germany, France and the Netherlands.
In 2016, the company's business expanded as a result of the acquisition of the original anesthesiology portfolio from AstraZeneca.
In 2017, Aspen received the rights to a portfolio of hospital muscle relaxants as a result of a successful deal with GlaxoSmithKline.
Aspen supplies drugs manufactured in Europe and South Africa to Russia and the CIS. The company also decided to localize the full cycle production of low molecular weight heparin Fraxiparin® (nadroparin calcium) in Russia. The drug is planned to be manufactured at the facilities of the NANOLEK company in the Kirov region.
In total, Aspen Russia employs about 200 people.
In 2016, the company's business expanded as a result of the acquisition of the original anesthesiology portfolio from AstraZeneca.
In 2017, Aspen received the rights to a portfolio of hospital muscle relaxants as a result of a successful deal with GlaxoSmithKline.
Aspen supplies drugs manufactured in Europe and South Africa to Russia and the CIS. The company also decided to localize the full cycle production of low molecular weight heparin Fraxiparin® (nadroparin calcium) in Russia. The drug is planned to be manufactured at the facilities of the NANOLEK company in the Kirov region.
In total, Aspen Russia employs about 200 people.
